Quantcast

Latest Solvay Pharmaceuticals Inc. Stories

2014-02-27 12:27:41

LONDON, Feb. 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Parkinson's Disease Market 2012-2016 TechNavio's analysts forecast the Global Parkinson's Disease market to grow at a CAGR of 1.67 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in the aging population. The Global Parkinson's Disease market has also been witnessing the transition toward using drugs that have new...

2010-02-05 10:50:00

MARIETTA, Ga., Feb. 5 /PRNewswire-FirstCall/ -- Solvay Pharmaceuticals, Inc. announced today that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of...

2009-10-29 07:56:00

MARIETTA, Ga., Oct. 29 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced that Amanda Rudd has been awarded the title of 2009 Thriving Student Achiever for her creative entry expressing her dream for the future. In honor of the 17th year of the SolvayCARES(SM) scholarship program, Amanda was awarded an educational scholarship totaling $17,000. In September, Solvay Pharmaceuticals, Inc. announced that 40 students with cystic fibrosis (CF) who are pursuing higher education had each...

2009-10-26 10:00:00

MARIETTA, Ga., Oct. 26 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery. EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in...

2009-10-15 08:04:00

MARIETTA, Ga., Oct. 15 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that new data confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food....

2009-10-09 07:27:00

MARIETTA, Ga., Oct. 9 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI). EPI is a condition resulting from a deficiency in...

2009-08-24 13:20:00

LOS ANGELES, Aug. 24 /PRNewswire/ -- The following statement is being issued by The Rossbacher Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP, and Thompson Hine LLP pursuant to an Order of the Superior Court of the State of California, for the County of Los Angeles, Central Civil West: If You Made a Payment or Co-Payment For the Purchase of the Hormone Replacement Therapy Drugs Estratest or Estratest H.S. in California, You Could Benefit From A...

2009-07-07 11:00:00

MARIETTA, Ga., July 7 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced the commercial availability of CREON(R) (pancrelipase) Delayed-Release Capsules. Now available to be filled at pharmacies nationwide, CREON(R) was approved by the Food and Drug Administration (FDA) on April 30, 2009, for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. CREON(R) is the first and only pancreatic enzyme product (PEP) to receive FDA approval...

2009-05-01 07:03:00

- Therapy is medically-necessary for thousands of patients with exocrine pancreatic insufficiency due to cystic fibrosis or other conditions - MARIETTA, Ga., May 1 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved CREON(R) (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. CREON(R) is the first and only pancreatic enzyme...

2009-01-05 05:00:00

MARIETTA, Ga., Jan. 5 /PRNewswire-FirstCall/ -- Nine out of 10 women in the United States are unaware that if their husband or male partner experiences symptoms like fatigue, depressed mood and increased waistline it could be related to a condition known as low testosterone, or Low T, according to survey results announced today by Solvay Pharmaceuticals, Inc. For women resolving to talk to their husbands or boyfriends about making their health a priority this New Year, one important...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related